- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06421831
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients
A Multi-center, Open Label, Single-arm, Dose Ascending Clinical Trial for Evaluation of Safety and Efficacy of Gene Therapy Drug GC101 in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients
Study Overview
Detailed Description
The purpose of this trial is to evaluate safety and efficacy of gene therapy drug GC101 in SMA 3 patients. Open-label, dose-escalation clinical trials of GC101 will be conducted in multiple centers in China.
GC101 will be administrated intrathecally. Short-term safety will be evaluated in 52 weeks and enter long-term follow-up study of 5 years at will. Patients will be tested at baseline and followed up at various time points.
The primary analysis for efficacy will be assessed at 12 months after treatment with GC101 on the changes from baseline HFMSE (Hammersmith Functional Motor Scale Expanded) and RULM(Revised Upper Limb Module) scores for patients of age ≥ 6 years old.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: GeneCradle, Inc China
- Phone Number: +8613501380583
- Email: ind@bj-genecradle.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China
- Recruiting
- Beijing Tiantan Hospital, Capital Medical University
-
Contact:
- Kang Zhang
-
Principal Investigator:
- Zaiqiang Zhang
-
Principal Investigator:
- Yajie Wang
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ≥2 years of age on the day of signing the informed consent form;
- Genetic and clinical diagnosis of type 3 SMA with bi-allelic deletion of SMN1 of 5qSMA;
- Hammersmith Functional Motor Scale - Expanded (HFMSE) score is between 10 and 54 at screening;
- Female patients of childbearing age who are pregnant or lactating, as well as all enrolled patients (both male and female), should take effective contraceptive measures within 6 months after the treatment;
- Patients or patient's legal guardian(s) must be able to understand the purpose and risks of the study and voluntarily provide signed and dated informed consent prior to any study-related procedures being performed.
Exclusion Criteria:
- Patient who has participated in any previous gene therapy research trials;
- Patient who has AAV9 neutralizing antibody titer ≥1:200;
- Patient who has received Nusinersen within 120 days and Risdiplam within 15 days before treatment;
- Patient who requires invasive or non-invasive ventilatory support averaging≥16 hours/day at screening;
- SMN2 copy numbers >4;
- Patient who needs nasal or gastric tube feeding for eating;
- Patient who is positive for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen, hepatitis C antibody, or treponema pallidum antibody;
- Known allergy or hypersensitivity to prednisolone or other glucocorticosteroids or their excipients
- Severe contractures at screening that interfere with either the ability to attain/demonstrate functional measures or with the ability to receive intrathecal (IT) dosing;
- Patient who has other serious diseases, such as severe cardiovascular and cerebrovascular diseases, digestive system diseases, urinary system diseases, endocrine system diseases, hematological diseases, immune system diseases, nervous system diseases (including but not limited to epilepsy, meningitis, history of convulsions or seizures, cerebrospinal fluid circulation disorders), and mental illnesses, etc.;
- Patient with previous injuries (such as upper or lower limb fractures) or surgical operations that have not fully recovered or reached a stable state;
- Vaccination no longer than 2 weeks before treatment;
- Patient who has any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: single dose cohort
1.2x10^14 vg/person of GC101 delivered one-time intrathecally
|
Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken β-actin promoter
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events
Time Frame: 52 weeks
|
Frequency of treatment-related adverse events (AEs), serious adverse events (SAEs), and changes from baseline in relevant clinical laboratory tests
|
52 weeks
|
Change from baseline on Hammersmith Functional Motor Scale - Expanded (HFMSE) scores at Month 12
Time Frame: 52 weeks
|
HFMSE consists of 33 activities that can be scored one of three ways: 0 for unable to perform, 1 for performs with modification/adaptation, and 2 for performs without modification.
|
52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of patients whose HFMSE improvement ≥ 3 points at Month 12
Time Frame: 52 weeks
|
HFMSE ≥3 points:minimal clinically important differences (MCID) were considered for the outcomes:
|
52 weeks
|
Change from baseline on Revised Upper Limb Module (RULM) scores at Month 12
Time Frame: 52 weeks
|
RULM is a 20-item evaluation of upper limb function primarily used for those with SMA who are non-ambulatory (young children through adults).
|
52 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of patients whose Clinical Global Impression (CGI) is improved at Month 12
Time Frame: 52 weeks
|
52 weeks
|
|
The proportion of patients whose Motor Function Measure (MFM) is improved or maintained at Month 12
Time Frame: 52 weeks
|
52 weeks
|
|
Change from baseline of Forced Vital Capacity (FVC) at Month 12 ( for patients > 6 years)
Time Frame: 52 weeks
|
52 weeks
|
|
Change from baseline of Forced Expiratory Volume in 1 Second (FEV1) at Month 12 ( for patients > 6 years)
Time Frame: 52 weeks
|
52 weeks
|
|
Change from baseline of Maximal Inspiratory Pressure (MIP) at Month 12 ( for patients > 6 years)
Time Frame: 52 weeks
|
52 weeks
|
|
Change from baseline of Maximal Expiratory Pressure (MEP) at Month 12 ( for patients > 6 years)
Time Frame: 52 weeks
|
52 weeks
|
|
Change from baseline of 6 minutes walk test (6MWT) at Month 12 (for ambulatory patients)
Time Frame: 52 weeks
|
The 6MWT is used for ambulatory participants with SMA and measures the total distance walked in 6 minutes.
|
52 weeks
|
Change from baseline of SMA Independence Scale (SMAIS) at Month 12
Time Frame: 52 weeks
|
The SMA Independence Scale (SMAIS) is a self-reported questionnaire to assess the amount of assistance patients require to perform daily activities. Higher SMAIS scores indicate greater independence. (range: 0-44). |
52 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- JLJY-GC101-SMA-010
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spinal Muscular Atrophy Type 3
-
Marco CapogrossoRoche-GenentechRecruitingSpinal Muscular Atrophy Type 3 | Spinal Muscular Atrophy Type 4United States
-
Institut de Myologie, FranceInstitut RocheCompletedType 2 Spinal Muscular Atrophy | Type 3 Spinal Muscular AtrophyBelgium, France, Germany
-
Catalyst Pharmaceuticals, Inc.TerminatedSpinal Muscular Atrophy Type 3Italy
-
Marco CapogrossoRoche-GenentechNot yet recruitingSpinal Muscular Atrophy | Spinal Muscular Atrophy Type 3 | SMA | Spinal Muscular Atrophy Type II | Spinal Muscular Atrophy 4United States
-
The Hong Kong Polytechnic UniversityThe University of Hong Kong; Manchester Metropolitan UniversityTerminatedSpinal Muscular Atrophy Type 3Hong Kong
-
Istanbul Medipol University HospitalIstanbul UniversityRecruitingNeuromuscular Diseases | Spinal Muscular Atrophy Type 3Turkey
-
Washington University School of MedicineActive, not recruitingSpinal Muscular Atrophy | Spinal Muscular Atrophy Type 3 | Spinal Muscular Atrophy Type IIUnited States, Canada
-
Scholar Rock, Inc.CompletedNeuromuscular Diseases | Neuromuscular Manifestations | Atrophy | Muscular Atrophy | Spinal Muscular Atrophy | Muscular Atrophy, Spinal | Spinal Muscular Atrophy Type 3 | SMA | Spinal Muscular Atrophy Type 2United States, Spain, Italy, Netherlands
-
Scholar Rock, Inc.Active, not recruitingNeuromuscular Diseases | Neuromuscular Manifestations | Atrophy | Muscular Atrophy | Spinal Muscular Atrophy | Muscular Atrophy, Spinal | Spinal Muscular Atrophy Type 3 | SMA | Spinal Muscular Atrophy Type 2 | Anti-myostatinUnited States, Germany, Belgium, Spain, United Kingdom, Netherlands, France, Italy, Poland
-
Scholar Rock, Inc.Active, not recruitingNeuromuscular Diseases | Neuromuscular Manifestations | Atrophy | Muscular Atrophy | Spinal Muscular Atrophy | Muscular Atrophy, Spinal | Spinal Muscular Atrophy Type 3 | SMA | Anti-myostatin | Spinal Muscular Atrophy Type IIUnited States, Spain, Belgium, Germany, Netherlands, Poland, Italy, France, United Kingdom
Clinical Trials on GC101
-
GeneCradle IncRecruitingSpinal Muscular AtrophyChina
-
GeneCradle IncRecruiting
-
Shanghai Juncell TherapeuticsRecruitingMelanoma | Efficacy | Adverse Drug Event | Safety | Tumor Infiltrating LymphocytesChina